<DOC>
	<DOCNO>NCT01001338</DOCNO>
	<brief_summary>To compare proportion subject whose serum urate ( sUA ) level &lt; 6.0 mg/dL follow 4 week continuous treatment RDEA594 combination allopurinol allopurinol alone subject document inadequate hypouricemic response standard dose allopurinol .</brief_summary>
	<brief_title>Allopurinol Combination Study</brief_title>
	<detailed_description />
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Lesinurad</mesh_term>
	<criteria>1 . Male postmenopausal surgically sterile female . 2 . 18 80 year age . 3 . Has take allopurinol sole urate lower therapy hyperuricemia least 6 week dose 200 mg 600 mg per day without adequate response . 4 . Has sUA level â‰¥ 6 mg/dL screening . 5 . Meets criteria diagnosis gout per American Rheumatism Association ( ARA ) Criteria Classification Acute Arthritis Primary Gout . 6 . Willing able give inform consent adhere visit/protocol schedule ( informed consent must give first study procedure perform ) . 7 . Subjects enter optional Extension Period must complete 28 day dose DoubleBlind Treatment Period Day 42 Visit Followup Period within 4 month must experience serious adverse event consider possibly relate study drug . 8 . Subjects enter optional OpenLabel Extension Period must continue compliant protocol Week 44 DoubleBlind Extension Period must experience serious adverse event consider possibly relate study drug . 1 . Consumes 14 drink alcohol per week ( e.g. , 1 drink = 5 oz [ 150 ml ] wine , 12 oz [ 360 ml ] beer , 1.5 oz [ 45 ml ] hard liquor ) . 2 . History suspicion drug abuse . 3 . History document suspected kidney stone . 4 . Has rheumatoid arthritis autoimmune disease require treatment . 5 . Documented suspicion HIV infection . 6 . Positive serology HCV antibody ( Abs ) , and/or hepatitis B surface antigen ( HBsAg ) . 7 . History malignancy within 5 year prior first dose study medication , nonmelanomatous skin cancer cervical dysplasia . 8 . History cardiac abnormality , include abnormal clinically relevant ECG change 9 . Any condition predispose QT prolongation include pathological Qwave ( define Qwave &gt; 40 msec depth &gt; 0.40.5 mV ) . 10 . Any use concomitant medication prolong QT/QTc interval within 14 day prior Baseline ( Day 1 ) . 11 . QT interval correct heart rate accord Fridericia ( QTcF ) &gt; 450 msec Screening predose Baseline ( Day 1 ) . 12 . Uncontrolled hypertension ( 150/95 ) . 13 . Inadequate renal function [ serum creatinine &gt; 1.5 mg/dL creatinine clearance &lt; 60 mL/min ( CockroftGault formula ) ] . 14 . Hemoglobin &lt; 10 g/dL ( male ) &lt; 9 g/dL ( female ) . 15 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2.5 x upper limit normal ( ULN ) . 16 . Gamma glutamyl transferase ( GGT ) &gt; 3 x ULN . 17 . Active peptic ulcer disease require treatment . 18 . History xanthinuria , active liver disease , hepatic dysfunction . 19 . Requires therapy uratelowering medication , study medication . 20 . Requires longterm use salicylate ; diuretic ; losartan ; azathioprine ; mercaptopurine ; theophylline ; intravenous colchicine ; cyclosporine ; cyclophosphamide ; pyrazinamide ; sulfamethoxazole ; trimethoprim . 21 . Taking medication know enzyme inducer ( see section 3.7 listing ) . 22 . Reports receive strong moderate inhibitor CYP3A4 Pgp inhibitor within 1 month prior study drug dosing , due potential interaction colchicine . 23 . Acute gout flare ( exclusive chronic synovitis/ arthritis ) ScreeningPeriod resolve one week prior Baseline Visit ( Day 0 ) . 24 . Pregnant breast feeding . 25 . Has receive investigational medication within 4 week prior screen visit study . 26 . Previously participate clinical study involve RDEA806 RDEA594 . 27 . Known hypersensitivity allergy RDEA594 , allopurinol colchicine component formulation . 28 . Body mass index ( BMI ) &gt; 48 kg/m2 . 29 . Taking great 1000 mg/day Vitamin C. 30 . Any medical psychological condition , opinion Investigator and/or Medical Monitor , might create undue risk subject interfere subject 's ability comply protocol requirement , complete study . 31 . Inadequate renal function complete DoubleBlind Treatment period prior enter DoubleBlind Extension Period . 32 . Requiring treatment prohibit medication note exclusion criterion number 2023 complete DoubleBlind Treatment Period prior enter Extension Period . 33 . Clinically relevant medical event determine investigator consultation medical monitor prior enter Extension Period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>